Study S000258

Effects of Glucagon-Like Peptide-1 Agonists on Metabolism and Ectopic Fat Deposition in Chronic Kidney Disease: A Pilot and Feasibility Study

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05254418
Acronym: GLIMP
Study type: INTERVENTIONAL
Phase: PHASE2
Masking: NONE
Status: COMPLETED
Enrollment: 7
Start: 2022-03-15
Primary completion: 2024-05-01
Lead sponsor: Vanderbilt University Medical Center
Conditions: Chronic Kidney Diseases
Interventions: DRUG:dulaglutide injection
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Changes in Intermuscular Fat Deposition as Assessed by Magnetic Resonance Imaging (MRI). [16 weeks]
Changes in Skeletal Muscle Mitochondrial Function as Assessed by Phosphocreatine Recovery Time Constant by 31P Magnetic Resonance Spectroscopy (31P-MRS). [16 weeks]
Changes in Physical Performance as Assessed by Systemic Physical Performance Battery Test [16 weeks]
Safety and Feasibility of Dulaglutide Treatment as Evaluated by Subject Interview, Continuous Glucose Monitoring, Adverse Events (AE), Laboratory Tests, Vital Signs, ECG & Allergic/Hypersensitivity Reactions. [16 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.